Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008057 | 0.89 | CYP1A2 (0.58) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| SCHEMBL8851492 | 0.85 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| SCHEMBL3623945 | 0.82 | CYP1A2 (0.50) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| SCHEMBL1680418 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| SCHEMBL30365968 | 0.76 | CYP1A2 (0.59) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| SCHEMBL47 | 0.76 | CYP1A2 (0.59) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| SCHEMBL16623289 | 0.75 | CYP1A2 (0.52) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| SCHEMBL16217107 | 0.75 | CYP1A2 (0.53) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| SCHEMBL18381479 | 0.75 | CYP2C19 (0.52) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 | |
| SCHEMBL6989114 | 0.74 | CYP2D6 (0.48) | CYP1A2CYP2C19CYP2D6CYP2C9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6319904-B1 | USEFUL AS AN ANTIULCER AGENT, SHOWING POTENT ANTI-HELICOBACTER PYLORI ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| US-20010027192-A1 | Formulation comprising antibacterial substance and antiulcer substance | AKIYAMA YOHKO (JP) | 2001-10-04 | — | — | US | disclosed |
| EP-0642797-B1 | Formulation comprising antibacterial substance and antiulcer substance | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-05-17 | — | — | EP | disclosed |
| EP-0995447-A1 | Formulation comprising antibacterial substance and antiulcer substance | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-5948773-A | Formulation comprising antibacterial substance and antiulcer substance | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| US-5840917-A | ADMINISTERING TO MAMMAL TO ERADICATE HELICOBACTER PYLORI | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0852498-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-07-15 | — | — | EP | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
| WO-1997011705-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-03 | — | — | WO | disclosed |
| WO-1996038175-A1 | STABILIZED COMPOSITION COMPRISING AN ANTIULCERATIVE BENZIMIDAZOLE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-05 | — | — | WO | disclosed |
| US-5536735-A | BENZIMIDAZOLE ANTIULCER AGENT, WATER SOLUBLE HETEROCYCLIC CARBOXYLIC AMIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-16 | — | — | US | disclosed |
| WO-1996007421-A2 | AN ANTIULCER MEDICINE COMPRISING A PROTEIN POSSESSING ALL GROWTH FACTOR ACTIVITY AND A PROTON PUMP INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-14 | — | — | WO | disclosed |
| EP-0649655-A1 | Injectable solutions containing anti-ulcer benzimidazoles and amides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-04-26 | — | — | EP | disclosed |
| EP-0645390-A1 | Trisubstituted pyrimido 5,4-d pyrimidines for modulating multidrug resistance, drugs containing these compounds and processes for their preparation | Dr. Karl Thomae GmbH (DE) | 1995-03-29 | — | — | EP | disclosed |
| EP-0642797-A1 | Formulation comprising antibacterial substance and antiulcer substance | Takeda Chemical Industries, Ltd. (JP) | 1995-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027192-A1 | Formulation comprising antibacterial substance and antiulcer substance | FABP6, VIP, FABP2 | CYP1A2 1720/4885CYP2C19 825/4885CYP2D6 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.